Pegfilgrastim is a PEGylated form of the recombinant human G-CSF analogue, filgrastim. It is used to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with nonmyeloid cancer receiving myelosuppressive anticancer treatment. It is also used to mobilize peripheral blood progenitor cells for collection and subsequent use in autologous or allogeneic peripheral blood stem cell transplantation and in the management of chronic neutropenia (congenital, cyclic, or idiopathic), and for persistent neutropenia in patients with advanced human immunodeficiency virus (HIV) infection. It is also indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome).
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Pegfilgrastim, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.